Molecular interactions and restoration strategies of PTEN and p53 in gliomas

胶质瘤中 PTEN 和 p53 的分子相互作用和修复策略

• 批准号: 8256629
• 负责人: Roger Abounader
• 金额: $ 31万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8256629
• 关键词: 1-Phosphatidylinositol 3-Kinase; Address; Animals; Binding; Cell Death Inhibition; Cells; Clinical; Complex; Data; Data Analyses; Event; Exhibits; Frequencies; Future; Genetic; Genetic Transcription; Glioblastoma; Glioma; Growth; Growth and Development function; Half-Life; Human; Individual; Inhibition of Cell Proliferation; Lead; Malignant Glioma; Malignant Neoplasms; Mediating; Molecular Conformation; Mutate; Mutation; Neoplasms; Null Lymphocytes; Oncogenic; Operative Surgical Procedures; Outcome; PTEN gene; Patients; Pharmaceutical Preparations; Process; Property; Protein p53; Proteins; Specimen; Testing; The Cancer Genome Atlas; Therapeutic; Time; Translating; Tumor Suppressor Proteins; Xenograft procedure; base; clinical application; gain of function; in vivo; knock-down; mutant; neoplastic cell; novel; outcome forecast; prognostic; promoter; protein degradation; public health relevance; restoration; small molecule; text searching; tumor; tumor growth; tumor xenograft

DESCRIPTION (provided by applicant): PTEN and p53 are the most frequently mutated tumor suppressors in human cancer, including gliomas. Recent evidence shows that wild-type PTEN and wild-type p53 (wt-p53) enhance each other's tumor suppressive functions. Wt-p53 induces PTEN gene transcription and wt-PTEN protects wt-p53 protein from degradation. We recently found, for the first time, that PTEN has unexpected tumor promoting properties in some glioma cells and tumor xenografts. We have preliminary evidence that PTEN acquires these unexpected tumor promoting properties by enhancing the half-life and oncogenic effects of gain-of-function p53 mutants (mut-p53). Based on these findings, we formulate the following novel hypothesis: PTEN tumor suppressor can exhibit tumor promoting properties in the setting of gain-of-function mut-p53. Therefore, therapeutic strategies that aim at restoring PTEN expression or function could lead to varying effects that depend on the mutational status of p53. To test this hypothesis and its prognostic, mechanistic, functional and therapeutic implications, we propose the following studies: In aim #1, we will use a large number of banked human glioblastoma specimens to determine the association between the combined PTEN/p53 mutational status and clinical outcome. In aim #2, we will investigate the mechanism through which PTEN regulates mut-p53 protein levels and function. In aim #3, we will assess the in vivo effects of restoring PTEN to glioma tumors with varying p53 mutational status. In aim #4, we will determine if small molecule modulators of p53 can reverse the tumor promoting effects of PTEN in mut-p53 cells and tumors. The results from all aims will be assessed for their consistency with the hypothesis. Successful completion of the studies proposed in this application would: 1) establish the combined PTEN/p53 status as a prognostic parameter (aim 1), 2) uncover previously unknown mechanistic and functional interactions between PTEN and mut-p53 (aim 2), 3) determine conditions and strategies for a successful therapeutic restoration of PTEN (aim 3), and 4) have important clinical implications for the use of small molecule modulators of p53 by identifying a subset of tumors that are more sensitive to these drugs and providing a rationale for their combination with PTEN restoration (aim 4). PUBLIC HEALTH RELEVANCE: We recently discovered that the tumor suppressor PTEN can have surprising tumor promoting properties. We have evidence that these unexpected properties depend on mutations of the tumor suppressor p53. We propose to study the interactions between PTEN and p53 mutations. We also propose to determine the conditions and test new strategies for successful tumor suppressor restoration to human tumors. The findings will have important implications on determining patient prognosis and developing new therapies against human cancers.

描述（由申请人提供）：PTEN和p53是人类癌症中最常见的突变肿瘤抑制因子，包括胶质瘤。最近的证据表明，野生型PTEN和野生型p53 （wt-p53）相互增强肿瘤抑制功能。Wt-p53诱导PTEN基因转录，wt-PTEN保护Wt-p53蛋白免受降解。我们最近首次发现PTEN在一些胶质瘤细胞和肿瘤异种移植物中具有意想不到的促瘤特性。我们有初步的证据表明，PTEN通过增强功能获得型p53突变体（mut-p53）的半衰期和致癌作用，获得了这些意想不到的促肿瘤特性。基于这些发现，我们提出了以下新的假设：PTEN肿瘤抑制因子在mut-p53功能获得的情况下可以表现出促进肿瘤的特性。因此，旨在恢复PTEN表达或功能的治疗策略可能会导致依赖于p53突变状态的不同效果。为了验证这一假设及其预后、机制、功能和治疗意义，我们提出以下研究：在目标#1中，我们将使用大量储存的人类胶质母细胞瘤标本来确定PTEN/p53联合突变状态与临床结果之间的关系。在目标#2中，我们将研究PTEN调节mutp53蛋白水平和功能的机制。在目标#3中，我们将评估在具有不同p53突变状态的胶质瘤肿瘤中恢复PTEN的体内效果。在aim #4中，我们将确定p53的小分子调节剂是否可以逆转PTEN在mutp53细胞和肿瘤中的促肿瘤作用。所有目标的结果将评估其与假设的一致性。成功完成本申请所建议的研究将：1)建立PTEN/p53联合状态作为预后参数（目标1），2)揭示PTEN和mutp53之间先前未知的机制和功能相互作用（目标2），3)确定PTEN成功治疗恢复的条件和策略（目标3）。4)通过识别对这些药物更敏感的肿瘤亚群，并为它们与PTEN恢复的联合提供理论依据，对p53小分子调节剂的使用具有重要的临床意义（目标4）。